Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) - Investment analysts at HC Wainwright lowered their Q3 2026 earnings estimates for shares of Niagen Bioscience in a research note issued on Wednesday, August 5th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.02 per share for the quarter, down from their prior estimate of $0.08. HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Niagen Bioscience's current full-year earnings is $0.21 per share. HC Wainwright also issued estimates for Niagen Bioscience's Q1 2027 earnings at $0.03 EPS, Q2 2027 earnings at $0.03 EPS, Q3 2027 earnings at $0.04 EPS and Q4 2027 earnings at $0.05 EPS.
A number of other equities analysts have also recently issued reports on NAGE. Freedom Capital upgraded Niagen Bioscience to a "strong-buy" rating in a report on Monday, July 6th. Weiss Ratings restated a "hold (c)" rating on shares of Niagen Bioscience in a research report on Friday, July 17th. Roth Capital restated a "buy" rating on shares of Niagen Bioscience in a research report on Wednesday. Canaccord Genuity Group cut their target price on Niagen Bioscience from $13.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, May 5th. Finally, Wall Street Zen cut shares of Niagen Bioscience from a "buy" rating to a "hold" rating in a research report on Saturday, April 25th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $10.33.
Read Our Latest Stock Report on Niagen Bioscience
Niagen Bioscience Stock Down 14.7%
NASDAQ NAGE opened at $2.96 on Thursday. The stock's 50-day simple moving average is $3.41 and its two-hundred day simple moving average is $4.34. Niagen Bioscience has a twelve month low of $2.87 and a twelve month high of $11.29. The company has a market capitalization of $235.73 million, a price-to-earnings ratio of 16.45 and a beta of 2.09.
Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. The company had revenue of $29.78 million during the quarter, compared to analyst estimates of $29.95 million. Niagen Bioscience had a net margin of 12.39% and a return on equity of 18.31%.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. New York State Teachers Retirement System bought a new stake in shares of Niagen Bioscience in the 4th quarter valued at about $30,000. Ameritas Investment Partners Inc. purchased a new position in Niagen Bioscience in the 3rd quarter worth approximately $45,000. Quantbot Technologies LP purchased a new position in Niagen Bioscience in the 3rd quarter worth approximately $48,000. Polymer Capital Management US LLC bought a new stake in Niagen Bioscience in the third quarter valued at approximately $96,000. Finally, BNP Paribas Financial Markets bought a new stake in Niagen Bioscience in the third quarter valued at approximately $96,000. Hedge funds and other institutional investors own 15.41% of the company's stock.
About Niagen Bioscience
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
